ClinicalTrials.gg
RecruitingNCT06666257GEMUpdated Oct 9, 2026

Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancies - The GEM Study

An interventional study of Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy in Pregnancies at Increased Risk for Excessive Gestational Weight Gain, Ecological Momentary Assessment and Intervention and Continuous Glucose Monitor, sponsored by Arkansas Children's Hospital Research Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Arkansas Children's Hospital Research Institute · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 9, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Obesity by Arkansas Children's Hospital Research Institute — 3 open to participants now, 5 under way, none of them phase 3. Obesity · Arkansas Children's Hospital Research Institute.

Started
2025
with 1 other
No phase
9 of 12
3 open now
Registered
10th of 12
by date

Among the 12 studies in Obesity by Arkansas Children's Hospital Research Institute, this one is one of 2 that started in 2025, is one of 9 with no phase, and was the 10th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

3 of the 12 studies in Obesity by Arkansas Children's Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Obesity by Arkansas Children's Hospital Research Institute, or all of them as a file.
02

Study summary

This single-arm pilot study will evaluate the feasibility and acceptability of a remotely delivered behavioral lifestyle intervention, adapted from the SmartMoms framework, to promote health gestational weight gain in pregnant women with overweight and obesity. Twelve to sixteen participants will receive weekly virtual motivational interview sessions with trained health coaches, review their daily weight data, step count, and continuous glucose monitoring data, and tailored guidance on physical activity and nutrition. Educational content will be delivered electronically, with peer support provided through a closed online group. A simulated (mock) control arm will be created post hoc from existing records for preliminary comparisons; all enrolled participants will receive the intervention.

Read the detailed description

The purpose of this study is to assess the feasibility of delivering a remotely administered behavioral lifestyle intervention for pregnant women with overweight and obesity, adapted from the established SmartMoms framework, using a simulated (mock) control arm for comparison. This pilot study will enroll approximately 12-16 participants and will focus on evaluating feasibility, acceptability, and preliminary signals of impact to inform a future randomized controlled trial.

The intervention is tailored to the needs of women in Arkansas and aims to promote healthy gestational weight gain through motivational interviewing, physical activity promotion, education on dietary recommendations and self-monitoring. Participants will be encouraged to meet current pregnancy exercise guidelines (>= 30 minutes of moderate-intensity activity on most, if not all days) and to follow a balanced diet consistent with caloric intake recommendations for appropriate gestational weight gain based on individual pre-pregnancy BMI.

Each participant will be provided with an internet connected bodyweight scal, and pedometer for daily self-monitoring. These devices will automatically transmit weight and step data to the study team. Participants will also wear a continuous glucose monitor (CGM) throughout their pregnancy to track temporal glucose patterns, which will be reviewed with the study's registered dietitian (RD) and health coaches.

Intervention delivery will include weekly virtual motivational interview sessions with a trained health coach. Sessions will review weight gain trajectory, dietary intake, physical activity patterns, and CGM data, and will provide tailored behavioral strategies for meeting gestational weight gain goals. Educational materials will be delivered electronically to participants' smartphones. A closed online forum will be available for peer support, following the SmartMoms framework.

The simulated control arm will be generated post hoc by matching trial participants to publicly available datasets based on gestational age, BMI category, and other relevant covariates. This mock control will serve only as a comparator for preliminary analyses; all enrolled participants will receive the active intervention.

The intervention will begin between 16-20 weeks' gestation and continue until delivery (20-24 weeks per participant). All motivational interviewing sessions will be delivered remotely, and participants will be trained individually on safe and effective use of study tools.

03

Conditions studied

  • Pregnancies at Increased Risk for Excessive Gestational Weight Gain
  • Ecological Momentary Assessment and Intervention
  • Continuous Glucose Monitor

Keywords

  • Pregnancy
  • Obesity
  • Continuous Glucose Monitoring
  • Ecological Momentary Intervention
  • Gestational Weight Gain
  • Overweight
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The formative phase (Phase I), classified as exempt by the institutional review board will seek participation from individuals meeting the following criteria:

  1. Currently pregnant or pregnant within the past 36 months.
  2. Community partners with relevant perspectives to inform recruitment, adaptation approaches and feasibility of the phase 2 pilot trial.

Clinical Trial (Phase 2)

Inclusion criteria

Inclusion Criteria:

  • pregnant women less than 20 weeks of gestation at time of screening
  • 18-45 years of age
  • of 25 - 40 kg/m-2
  • Expecting a singleton pregnancy
  • Smartphone and/or reliable internet access
  • Willing to be identifiable to other study participants in the study program .

Exclusion criteria

Exclusion Criteria:

  • Smoker
  • Preexisting medical conditions that might be exacerbated by pregnancy (e.g., diabetes mellitus, chronic renal failure, hypertension, , seizure disorder, lupus, drug or alcohol abuse, serious psychiatric disorders)
  • Current mental health or eating disorder
  • to exercise (OB/GYN release is obtained prior to consent)
  • Conceived with assisted fertility treatments
  • Medications during pregnancy known to influence fetal growth (e.g., thyroid hormone, , insulin, oral hypoglycemic agents)
  • Plans to move out of the state in the next 6 months following screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Remote Weight & Step Monitoring + CGM

    Women will engage in the remote intervention resembling efforts used by the SmartMoms intervention, but adapted to the needs of Arkansas women while also wearing unblinded CGM devices providing insights to glycemic trends in response to lifestyle factors.

    Behavioral: Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy

Interventions

  • BehavioralContinuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy

    The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be discussed with participants during motivational interviewing. For the CGM piece, participants will wear unblinded CGM devices and have access to CGM linked app features that allow insights and reactivity to personal glycemic data

06

What researchers measure

Primary outcomes

  1. Feasibility data of the modified EMI: AR-GEM Study - Recruitment and Retention

    Maternal recruitment and retention rates (total number of participants recruited and retained)

    Time frame: continuous, from study enrollment at 16-20 weeks until study completion, an average of 6 months

  2. Feasibility data of the modified EMI: SmartMomsAR - Acceptability

    Acceptability scores from online intervention satisfaction questionnaires, 5 point Likert Scale system

    Time frame: continuous, from study enrollment at 16-20 weeks until study completion, an average of 6 months

  3. Feasibility data of the modified EMI: SmartMomsAR - Protocol Adherence

    Adherence to study protocol via process measures. (Percentage of complete data points)

    Time frame: continuous, from study enrollment at 16-20 weeks until study completion, an average of 6 months

Secondary outcomes

  1. Incidence of appropriate gestational weight gain per 2009 NASM guidelines.

    Frequencies (percentage) of appropriate gestational weight gain incidence. Maternal weight (lbs) over time.

    Time frame: data is derived through study completion, an average of 6 months.

  2. Change in healthful lifestyle behaviors - HEI

    Change scores for healthy eating index (HEI)

    Time frame: data is derived through study completion, an average of 6 months.

  3. Change in healthful lifestyle behaviors - Steps (Physical Activity)

    Change scores for physical activity counts (steps) as assessed commercial accelerometer.

    Time frame: data is derived through study completion, an average of 6 months.

  4. Change in healthful lifestyle behaviors - Glycemic profile

    Summary of glycemic profile data (mg/dL) as assessed by CGM.

    Time frame: data is derived through study completion, an average of 6 months.

07

Study locations

1 of 1 sites recruiting
  • Arkansas Children's Research Institute - Arkansas Children's Nutrition Center, University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
    Recruiting
    • Elizabeth Hayes, Recruitment Coordinator · ContactACNCStudies@uams.edu · 501-364-3309
    • Lisa T Jansen, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Within 21 days of having IRB approval for the finalized phase II protocol (anticipated to be available 05/01/25)

Access criteria: Individual participant data (IPD) from this feasibility pilot study will be shared with qualified researchers conducting analyses that align with the study's objectives, specifically in relation to [study-specific areas of interest, e.g., behavior modification in pregnancy, glucose metabolism, etc.]. All data requests must include a detailed research proposal outlining planned analyses and the statistical methods. Proposals will be reviewed by the Principal Investigator and an independent review board for scientific validity, ethical considerations, and alignment with study objectives. A Data Sharing Agreement (DSA) must be signed prior to data release. Documents can be submitted via [email/portal], and requests will be reviewed within [timeframe]. Data will be shared via a secure, restricted-access repository.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 28 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 28 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Oct 2025 → Mar 2025, primary completion Apr 2026 → Jul 2027 and completion Jul 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2024
First posted
Oct 30, 2024
StartActual
Mar 1, 2025was Oct 2025
Primary completionEst.
Jul 30, 2027was Apr 2026
CompletionEst.
Sep 30, 2027was Jul 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
1 site added — first site in United States
Show site
  • Arkansas Children's Research Institute - Arkansas Children's Nutrition Center, University of Arkansas for Medical Sciences · Little Rock, United States
Oct 9, 2026
Start date
Oct 1, 2025→Mar 1, 2025 (actual)
Oct 9, 2026
Primary completion
Apr 30, 2026→Jul 30, 2027
Oct 9, 2026
Study completion
Jul 30, 2026→Sep 30, 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in United States
    Show site
    • Arkansas Children's Research Institute - Arkansas Children's Nutrition Center, University of Arkansas for Medical Sciences · Little Rock, United States
    Start date Oct 1, 2025→Mar 1, 2025 (now actual)
    Primary completion Apr 30, 2026→Jul 30, 2027
    Study completion Jul 30, 2026→Sep 30, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06666257
Responsible party
Lisa Jansen (Assistant Professor, Arkansas Children's Hospital Research Institute) — Principal investigator
First posted
Oct 30, 2024
Start date
Mar 1, 2025
Primary completion
Jul 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Lisa T Jansen, PhD
Contact
ltjansen@uams.edu
5013646516
Sharon E Sanders, PhD, MPH, CHES
Contact
SESanders@uams.edu
501-364-5118
Lisa T Jansen, PhD
principal investigator · Arkansas Children's Hospital Research Institute; University of Arkansas for Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion